Groves Donald, Mihos Christos G, Larrauri-Reyes Maiteder, Santana Orlando
From the *University of Miami Miller School of Medicine, Miami, FL; and †Columbia University Division of Cardiology at the Mount Sinai Heart Institute, Miami Beach, FL.
Cardiol Rev. 2016 Sep-Oct;24(5):224-9. doi: 10.1097/CRD.0000000000000090.
The hydroxy-methyl-glutaryl-CoA reductase inhibitors (statins) are used extensively in the treatment of hyperlipidemia and in the primary and secondary prevention of cardiovascular and cerebrovascular diseases. Statins have also been demonstrated to confer secondary pleiotropic benefits in a variety of other disease processes, including a potential advantage in treating and preventing atrial fibrillation. These effects are primarily due to the up-regulation of endothelial nitric oxide synthase activity and a decrease in nicotinamide adenine dinucleotide phosphate oxidase production, which leads to downstream effects that improve the electromechanical function of atrial and myocardial tissue. The following serves as a focused and updated review of the published clinical data regarding the pleiotropic effects of statins in atrial fibrillation.
羟甲基戊二酰辅酶A还原酶抑制剂（他汀类药物）被广泛用于治疗高脂血症以及心血管和脑血管疾病的一级和二级预防。他汀类药物还被证明在多种其他疾病过程中具有次要的多效性益处，包括在治疗和预防心房颤动方面具有潜在优势。这些作用主要归因于内皮型一氧化氮合酶活性的上调和烟酰胺腺嘌呤二核苷酸磷酸氧化酶产生的减少，这会导致改善心房和心肌组织机电功能的下游效应。以下是对已发表的关于他汀类药物在心房颤动中多效性作用的临床数据的重点和最新综述。
